within Pharmacolibrary.Drugs.ATC.J;

model J05AR18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.083,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR18</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination antiretroviral medication containing emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat, primarily used for the treatment of HIV-1 infection in adults and adolescents. It is approved and widely used as a single-tablet regimen for HIV management.</p><h4>Pharmacokinetics</h4><p>Steady-state pharmacokinetics in healthy adult subjects after oral administration of the fixed-dose combination tablet under fed conditions.</p><h4>References</h4><ol><li><p>Natukunda, E, et al., &amp; Rhee, MS (2017). Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. <i>The Lancet. Child &amp; adolescent health</i> 1(1) 27–34. DOI:<a href=\"https://doi.org/10.1016/S2352-4642(17)30009-3\">10.1016/S2352-4642(17)30009-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30169223/\">https://pubmed.ncbi.nlm.nih.gov/30169223</a></p></li><li><p>Yamada, H, et al., &amp; Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. <i>Clinical pharmacology in drug development</i> 7(2) 132–142. DOI:<a href=\"https://doi.org/10.1002/cpdd.365\">10.1002/cpdd.365</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28581645/\">https://pubmed.ncbi.nlm.nih.gov/28581645</a></p></li><li><p>Sax, PE, et al., &amp; McCallister, S (2014). Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. <i>Journal of acquired immune deficiency syndromes (1999)</i> 67(1) 52–58. DOI:<a href=\"https://doi.org/10.1097/QAI.0000000000000225\">10.1097/QAI.0000000000000225</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24872136/\">https://pubmed.ncbi.nlm.nih.gov/24872136</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR18;
